Vanguard Group’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Vanguard Group’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,859,306	Closed	-$1.62M	–	4172
2019 Q2	$1.62M	Buy	1,859,306 +907,318	+95%	+$1.42M	﹤0.01%	3532
2019 Q1	$2.21M	Buy	951,988 +713,965	+300%	+$1.93M	﹤0.01%	3416
2018 Q4	$552K	Sell	238,023 -429,796	-64%	-$3.79M	﹤0.01%	3717
2018 Q3	$9.9M	Buy	667,819 +67,240	+11%	+$1.07M	﹤0.01%	2926
2018 Q2	$9.12M	Buy	600,579 +220,870	+58%	+$3.75M	﹤0.01%	2948
2018 Q1	$7.13M	Buy	379,709 +180,719	+91%	+$3.16M	﹤0.01%	2990
2017 Q4	$3.61M	Buy	198,990 +69,875	+54%	+$1.48M	﹤0.01%	3251
2017 Q3	$2.87M	Buy	+129,115	New	+$2.83M	﹤0.01%	3299

Other funds holding SNNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Vanguard Group's SNNA Position: Q3 2019 in Review

Vanguard Group sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q3 2019, closing a stake of 1,859,306 shares — an estimated $1.62M sold.

Vanguard Group first reported a position in SNNA in Q3 2017 and held it in 8 quarters. The position peaked at $9.9M in Q3 2018. 23 funds tracked by Wall St. Rank hold SNNA as of Q3 2019.

Vanguard Group reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Vanguard Group sold 1,859,306 Sienna Biopharmaceuticals, Inc. shares in Q3 2019, an estimated $1.62M.
Vanguard Group first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2017 and held it in 8 quarters.
Vanguard Group's Sienna Biopharmaceuticals, Inc. position peaked at $9.9M in Q3 2018.
23 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q3 2019.

Based on Vanguard Group's 13F filing for Q3 2019, filed 14 Nov 2019.